Viavi Solutions shares rise on cybersecurity product launch and RSAC positioning

Viavi Solutions shares rise on cybersecurity product launch and RSAC positioning

Viavi Solutions shares rise on cybersecurity product launch and RSAC positioning

https://www.quiverquant.com/news/Viavi+Solutions+shares+rise+on+cybersecurity+product+launch+and+RSAC+positioning

Publish Date: 2026-03-18 17:22:00

Source Domain: www.quiverquant.com

Author:

Using an unordered list, summarize the following article with between 4 and 8 key points.

Viavi Solutions Inc. (VIAV) is up 4.9% today. Here is some analysis on what might have caused this price movement.Analysis: The move appears tied to VIAVI’s March 18 product announcement for Observer Threat Forensics, a NetSecOps-focused offering emphasizing retrospective (“look-back”) investigation across multiple telemetry types. Investors may be treating the launch and upcoming RSA Conference demonstrations as a positive signal for demand in enterprise security visibility and incident response workflows.Details:VIAVI announced Observer Threat Forensics with advanced retrospective analysis intended to unify packet, flow, and log telemetry in a single workflow for investigations.The offering is positioned to support post-detection breach analysis (e.g., validating the intrusion point and potential exposure) by improving cross-team visibility and reducing data gaps.VIAVI described the solution as combining its network operations management background with threat intelligence integrations to speed triage and root-cause work.VIAVI is marketing live demonstrations at RSA Conference 2026 (March 23–26 in San Francisco), including a scheduled session on March 24, which may be helping keep attention on the product rollout.Sources:VIAVI Solutions, VIAVI Solutions (Events)Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.$VIAV Insider Trading Activity$VIAV insiders have traded $VIAV stock on the open market 48 times in the past 6 months. Of those trades, 0 have been purchases and 48 have been sales.Here’s a breakdown of recent trading of $VIAV stock by insiders over the last 6 months:OLEG KHAYKIN (President & CEO) has made 0 purchases and 14 sales selling 619,224 shares for an estimated $13,900,937.KEITH BARNES has made 0 purchases and 4 sales selling 175,400 shares for an estimated $3,139,797.ILAN DASKAL (EVP, CFO) has made 0 purchases and 3 sales selling 170,000 shares for an estimated $2,972,993.GARY W STALEY (SVP Global Sales NSE) has made 0 purchases and 7 sales selling 90,069 shares for an estimated $2,289,155.DONALD A COLVIN has made 0 purchases and 3 sales selling 65,000 shares for an estimated $1,414,357.KEVIN CHRISTOPHER SIEBERT (SVP Gen. Counsel & Secretary) has made 0 purchases and 5 sales selling 66,141 shares for an estimated $1,357,751.RICHARD BELLUZZO has made 0 purchases and 3 sales selling 37,220 shares for an estimated $874,870.LUKE M SCRIVANICH (SVP General Manager OSP) has made 0 purchases and 3 sales selling 32,653 shares for an estimated $649,398.PAUL MCNAB (EVP, Chief Mktg & Stgy Officer) has made 0 purchases and 4 sales selling 22,463 shares for an estimated $486,172.RICHARD JOHN BURNS sold 3,384 shares for an estimated $63,483EUGENIA CORRALES sold 3,384 shares for an estimated $63,483To track insider transactions, check out Quiver Quantitative’s insider trading dashboard.$VIAV Hedge Fund ActivityWe have seen 221 institutional investors add shares of $VIAV stock to their portfolio, and 184 decrease their positions in their most recent quarter.Here are some of the largest recent moves:T. ROWE PRICE INVESTMENT MANAGEMENT, INC. removed 7,888,249 shares (-70.3%) from their portfolio in Q4 2025, for an estimated $140,568,597WOODLINE PARTNERS LP removed 4,438,187 shares (-88.7%) from their portfolio in Q4 2025, for an estimated $79,088,492WELLINGTON MANAGEMENT GROUP LLP removed 3,415,517 shares (-23.7%) from their portfolio in Q4 2025, for an estimated $60,864,512PARSIFAL CAPITAL MANAGEMENT, LP added 3,385,700 shares (+inf%) to their portfolio in Q4 2025, for an estimated $60,333,174POINT72 ASSET MANAGEMENT, L.P. removed 3,210,605 shares (-78.6%) from their portfolio in Q4 2025, for an estimated $57,212,981AMERIPRISE FINANCIAL INC added 2,184,183 shares (+139.1%) to their portfolio in Q4 2025, for an estimated $38,922,141INVESCO LTD. added 2,045,702 shares (+116.0%) to their portfolio in Q4 2025, for an estimated $36,454,409To track hedge funds’ stock portfolios, check out Quiver Quantitative’s institutional holdings dashboard.$VIAV Congressional Stock TradingMembers of Congress have traded $VIAV stock 1 times in the past 6 months. Of those trades, 0 have been purchases and 1 have been sales.Here’s a breakdown of recent trading of $VIAV stock by members of Congress over the last 6 months:To track congressional stock trading, check out Quiver Quantitative’s congressional trading dashboard.$VIAV Analyst RatingsWall Street analysts have issued reports on $VIAV in the last several months. We have seen 2 firms issue buy ratings on the stock, and 0 firms issue sell ratings.Here are some recent analyst ratings:Needham issued a “Buy” rating on 01/29/2026Stifel issued a “Buy” rating on 12/17/2025To track analyst ratings and price targets for $VIAV, check out Quiver Quantitative’s $VIAV forecast page.$VIAV Price TargetsMultiple analysts have issued price targets for $VIAV recently. We have seen 7 analysts offer price targets for $VIAV in the last 6 months, with a median target of $24.0.Here are some recent targets:Mike Genovese from Rosenblatt set a target price of $42.0 on 03/18/2026 Ryan Koontz from Needham set a target price of $36.0 on 03/02/2026 Mehdi Hosseini from Susquehanna set a target price of $25.0 on 01/29/2026 Ruben Roy from Stifel set a target price of $24.0 on 01/29/2026 Dave Kang from B. Riley Securities set a target price of $22.0 on 01/26/2026 Jim Kelleher from Argus Research set a target price of $23.0 on 11/05/2025 Andrew Spinola from UBS set a target price of $17.0 on 10/30/2025 This article is not financial advice. See Quiver Quantitative’s disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.